MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. The company has three marketed products and an advancing pipeline of promising candidates, all designed to treat or prevent a number of debilitating or life-threatening diseases.

MedImmune's state-of-the-art R&D facility and worldwide corporate headquarters is located in Gaithersburg, Maryland.

With approximately 3,000 employees worldwide, MedImmune is headquartered in Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom and the Netherlands. The company relocated its corporate headquarters to a new state-of-the-art facility in March 2004, designed to place research functions at the core and enhance the collaborative potential of researchers and developers.

The company's marketed products include Synagis^® (palivizumab), Ethyol^® (amifostine), and FluMist^® (Influenza Virus Vaccine Live, Intranasal), with additional products in clinical testing.